Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · Real-Time Price · USD
577.95
+2.26 (0.39%)
At close: Oct 24, 2025, 4:00 PM EDT
580.00
+2.05 (0.35%)
After-hours: Oct 24, 2025, 7:56 PM EDT
0.39%
Market Cap59.93B
Revenue (ttm)14.21B
Net Income (ttm)4.46B
Shares Out 103.69M
EPS (ttm)39.67
PE Ratio14.57
Forward PE14.70
Dividend$3.52 (0.61%)
Ex-Dividend DateAug 18, 2025
Volume875,427
Open579.65
Previous Close575.69
Day's Range576.20 - 582.70
52-Week Range476.49 - 952.02
Beta0.31
AnalystsBuy
Price Target785.05 (+35.83%)
Earnings DateOct 28, 2025

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 2, 1991
Employees 15,106
Stock Exchange NASDAQ
Ticker Symbol REGN
Full Company Profile

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial Statements

Analyst Summary

According to 22 analysts, the average rating for REGN stock is "Buy." The 12-month stock price target is $785.05, which is an increase of 35.83% from the latest price.

Price Target
$785.05
(35.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

We purchased several new fund holdings across various sectors. Sempra has been shifting its strategic focus from its highly regulated California operations to its growing presence in Texas. Regeneron ...

Other symbols: APDCNCCOFFIIQVIVZJNJ
2 days ago - Seeking Alpha

7 Stocks Taking The Next Step To Be On Offense

Bio-Rad Laboratories was a positive contributor after the company reported steadier earnings than the market expected. PVH also remains our largest share repurchaser for the year after buying a teens ...

Other symbols: ACIBIOCNXFCFFDXFISIAC
2 days ago - Seeking Alpha

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence...

9 days ago - GlobeNewsWire

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma New sa...

11 days ago - GlobeNewsWire

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer follow-up showed stability or continued improv...

13 days ago - GlobeNewsWire

What If You Were Missing The Value In Regeneron Pharmaceuticals Stock?

Here's why we believe Regeneron Pharmaceuticals (REGN) stock merits attention as a value addition. Currently, it is trading almost 44% lower than its 1-year peak and is also priced at a PS multiple be...

16 days ago - Forbes

US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer

The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals' immunotherapy, Libtayo, as an add-on treatment for skin cancer patients at high risk of their disease returning af...

17 days ago - Reuters

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0....

17 days ago - GlobeNewsWire

11 Cheap Stocks for a Market That's Too Expensive

Amid a pricey market, Evercore wanted to find stocks that are less pricey but have staying power. Here's how they did it and what they found.

Other symbols: DALFDXUAL
18 days ago - Barrons

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...

19 days ago - Seeking Alpha

Regeneron: Growth Catalysts Incoming

Regeneron Pharmaceuticals, Inc. is rated a Buy, supported by strong Dupixent and oncology growth offsetting Eylea/Eylea HD declines. REGN's robust pipeline, best-in-class products, and upcoming patent...

25 days ago - Seeking Alpha

Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025

TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday...

25 days ago - GlobeNewsWire

Final Trades: Nvidia, Amphenol, Regeneron and Lockheed Martin

CNBC's "Halftime Report" team detail their stock picks and final trades.

Other symbols: APHLMTNVDA
25 days ago - CNBC Television

Regeneron: Strong R&D Pipeline Drives Growth Outlook

Retail investors' fears over the launch of Eylea biosimilars are gradually fading amid the strong performance of Dupixent and Libtayo, actively gaining share in the PD-1 and PD-L1 inhibitors market. S...

4 weeks ago - Seeking Alpha

Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-densit...

4 weeks ago - GlobeNewsWire

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 24, 2025 10:30 AM EDT Company Participants Ryan Crowe - Sen...

4 weeks ago - Seeking Alpha

Regeneron: Looking For Green Shoots Of Growth On Top Of Heartwood Franchises

Regeneron Pharmaceuticals remains a top conviction idea, driven by strong Dupixent growth, a robust pipeline, and a healthy balance sheet. REGN's Q2 earnings showed solid revenue and EPS growth, with ...

4 weeks ago - Seeking Alpha

Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion

Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent sig...

Other symbols: SNY
4 weeks ago - GlobeNewsWire

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo

4 weeks ago - GlobeNewsWire

Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study

Regeneron said on Friday its experimental therapy showed either a complete or partial disappearance of a precancerous disorder, which manifests into blood cancer, in all patients in a mid-stage trial.

5 weeks ago - Reuters

Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks

Inmazeb ® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense , also known as Zaire   ebolavirus

5 weeks ago - GlobeNewsWire

Regeneron's bone disorder treatment succeeds in late-stage trial

Regeneron Pharmaceuticals said on Wednesday its experimental treatment for a rare genetic disorder that affects bone tissue has met the main goal of a late-stage trial.

5 weeks ago - Reuters

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation

FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation

5 weeks ago - GlobeNewsWire

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer

Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone

6 weeks ago - GlobeNewsWire

Regeneron Pharmaceuticals, Inc. (REGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Christopher Fenimore - Executive VP of Finance...

6 weeks ago - Seeking Alpha